TLDR
-
Lilly stock slips after announcing a $2.8B AtaiBeckley acquisition deal.
-
Buyout adds late-stage depression therapies to Lilly’s neuroscience pipeline.
-
BPL-003 advances toward Phase 3 with FDA Breakthrough Therapy status.
-
Deal includes milestone payments that could lift value to $3.8 billion.
-
Lilly expands treatment-resistant depression pipeline through acquisition.
Eli Lilly and Company (NYSE: LLY) shares slipped 0.10% to $1,155.52 after the company announced a $2.8 billion agreement to acquire AtaiBeckley. The stock gave up early gains after a sharp mid-morning decline before stabilizing near the session low. Meanwhile, the acquisition strengthens Lilly’s neuroscience portfolio and expands its pipeline for treatment-resistant depression.
Lilly Targets Next-Generation Depression Treatments
Lilly agreed to acquire all outstanding AtaiBeckley shares for $6.75 per share in cash at closing. Shareholders may receive up to $2.50 per share through contingent value rights tied to future milestones. Therefore, the total potential transaction value could reach approximately $3.8 billion.
The agreement values the upfront equity purchase at about $2.8 billion. The additional milestone payments could contribute another $1.0 billion if development and regulatory targets are achieved. Those payments depend on future clinical and regulatory progress.
The transaction is expected to close during the third quarter of 2026. It remains subject to shareholder approval, regulatory clearance, and other customary closing conditions. The purchase price represents about a 40% premium to AtaiBeckley’s 30-day volume-weighted average share price through July 15, 2026.
Acquisition Adds Late-Stage Neuroplastogen Programs
AtaiBeckley develops rapid-acting neuroplastogens for serious mental health conditions. The company’s lead candidate, BPL-003, is an intranasal synthetic form of 5-MeO-DMT for treatment-resistant depression. The program has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration.
BPL-003 reported rapid and durable reductions in depressive symptoms during a Phase 2b clinical study. Participants completed treatment during an average two-hour clinic visit, and benefits continued for months afterward. The program has already entered Phase 3 activities.
The company’s second leading program, VLS-01, uses a buccal film formulation of DMT. It currently advances through an ongoing Phase 2b clinical trial. Together, both programs aim to restore synaptic connectivity rather than mainly targeting neurotransmitter levels.
Transaction Structure and Strategic Background
The contingent value rights include three possible milestone payments. Shareholders may receive $1.00 per share after a Phase 3 trial begins for VLS-01 before the fourth anniversary. Additionally, another $0.50 depends on U.S. approval and DEA rescheduling of BPL-003 before the fifth anniversary.
A final $1.00 payment depends on U.S. approval and DEA rescheduling of VLS-01 before the seventh anniversary. The complete value depends on future regulatory and development success. Lilly stated no assurance exists that any contingent payments will occur.
Both companies’ boards approved the acquisition before announcing the agreement. Furthermore, Apeiron Investment Group, directors, and officers signed voting support agreements covering approximately 15% of outstanding shares. Goldman Sachs advised Lilly, while Moelis & Company, Centerview Partners, Latham & Watkins, Citi, and Ropes & Gray supported the transaction through financial and legal advisory roles.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
